GlaxoSmithKline (LON:GSK) had its price objective raised by research analysts at JPMorgan Chase & Co. from GBX 1,710 ($23.14) to GBX 1,740 ($23.55) in a research note issued on Monday, Price Targets.com reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s price target indicates a potential upside of 11.44% from the stock’s previous close.
GSK has been the subject of a number of other research reports. Credit Suisse Group set a GBX 1,400 ($18.94) price objective on GlaxoSmithKline in a report on Thursday, February 10th. Jefferies Financial Group set a GBX 1,925 ($26.05) target price on GlaxoSmithKline in a research note on Wednesday, February 9th. Liberum Capital increased their target price on GlaxoSmithKline from GBX 1,870 ($25.30) to GBX 1,910 ($25.85) and gave the stock a “buy” rating in a research note on Tuesday, February 15th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 1,500 ($20.30) target price on shares of GlaxoSmithKline in a research note on Wednesday, February 16th. Finally, Barclays reissued an “equal weight” rating and issued a GBX 1,675 ($22.67) target price on shares of GlaxoSmithKline in a research note on Friday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of GBX 1,657.29 ($22.43).
GSK traded down GBX 5.60 ($0.08) during trading on Monday, reaching GBX 1,561.40 ($21.13). The stock had a trading volume of 3,651,093 shares, compared to its average volume of 8,224,443. The stock’s 50 day moving average is GBX 1,622.45 and its two-hundred day moving average is GBX 1,526.85. The company has a current ratio of 0.79, a quick ratio of 0.54 and a debt-to-equity ratio of 113.27. The company has a market capitalization of £78.59 billion and a price-to-earnings ratio of 18.03. GlaxoSmithKline has a one year low of GBX 1,190.80 ($16.11) and a one year high of GBX 1,737 ($23.50).
In other GlaxoSmithKline news, insider Emma Walmsley sold 34,031 shares of the firm’s stock in a transaction dated Monday, February 14th. The stock was sold at an average price of GBX 1,610 ($21.79), for a total value of £547,899.10 ($741,406.09).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.